Literature DB >> 30541356

QRS Area Is a Strong Determinant of Outcome in Cardiac Resynchronization Therapy.

Antonius M W van Stipdonk1, Iris Ter Horst1,2, Marielle Kloosterman3, Elien B Engels4, Michiel Rienstra3, Harry J G M Crijns1,4, Marc A Vos5, Isabelle C van Gelder3, Frits W Prinzen4, Mathias Meine2, Alexander H Maass3, Kevin Vernooy1,4,6.   

Abstract

BACKGROUND: The combination of left bundle branch block (LBBB) morphology and QRS duration is currently used to select patients for cardiac resynchronization therapy (CRT). These parameters, however, have limitations. This study evaluates the value of QRS area compared with that of QRS duration and morphology in the association with clinical and echocardiographic outcomes in a large cohort of CRT patients.
METHODS: A retrospective multicentre study was conducted in 1492 CRT patients. LBBB morphology, QRS duration, and QRS area in the baseline 12-lead ECG were evaluated for their association with the occurrence of the combined primary end point of all-cause mortality, cardiac transplantation, and left ventricular assist device implantation. Secondary end points were heart failure hospitalization within the first year after implantation and echocardiographic reduction in left ventricular end-systolic volume.
RESULTS: During a mean follow-up period of 3.4 years, 32% of patients reached the primary end point. The association of QRS area with all outcomes was stronger than that of LBBB morphology and QRS duration separately and at least as strong as their combination. QRS area identified patients who did not experience the primary end point better than QRS morphology and QRS duration (area under the curve, 0.61 versus 0.55 and 0.51, respectively; P<0.001). Furthermore, QRS area identifies patients with echocardiographic remodeling in response to CRT better than QRS morphology and duration (area under the curve, 0.69 versus 0.58 and 0.58, respectively; P<0.001). QRS area was the only independent electrocardiographic determinant associated with the primary end point; hazard ratio, 0.50 (0.35-0.71). Furthermore, QRS area showed significant association with outcomes in both patients with and without LBBB and QRS ≥150 ms.
CONCLUSIONS: QRS area has a strong association to clinical and echocardiographic response to CRT, at least as strong as current patient selection parameters. QRS area may be particularly useful to predict CRT response in patients without a wide LBBB.

Entities:  

Keywords:  bundle-branch block; cardiac resynchronization therapy; heart failure; patient selection; stroke volume

Mesh:

Year:  2018        PMID: 30541356     DOI: 10.1161/CIRCEP.118.006497

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  23 in total

1.  Non-invasively quantified changes in left ventricular activation predict outcomes in patients undergoing cardiac resynchronization therapy.

Authors:  Daniel J Friedman; Kasper Emerek; Steen Møller Hansen; Christoffer Polcwiartek; Peter L Sørensen; Zak Loring; Joanne Sutter; Peter Søgaard; Joseph Kisslo; Claus Graff; Brett D Atwater
Journal:  J Cardiovasc Electrophysiol       Date:  2019-10-08

2.  Vectorcardiography-derived index allows a robust quantification of ventricular electrical synchrony.

Authors:  Juan M F Fernández; Damián N Spagnuolo; María T Politi; Iván A Tello Santacruz; Miguel Schiavone; César Cáceres Monié; Horacio A Avaca; Osvaldo Chara
Journal:  Sci Rep       Date:  2022-06-15       Impact factor: 4.996

3.  Lead one ratio in left bundle branch block predicts poor cardiac resynchronization therapy response.

Authors:  Zak Loring; Daniel J Friedman; Kasper Emerek; Claus Graff; Peter L Sørensen; Steen M Hansen; Bjorn Wieslander; Martin Ugander; Peter Søgaard; Brett D Atwater
Journal:  Pacing Clin Electrophysiol       Date:  2020-05-08       Impact factor: 1.976

4.  Machine Learning of 12-Lead QRS Waveforms to Identify Cardiac Resynchronization Therapy Patients With Differential Outcomes.

Authors:  Albert K Feeny; John Rickard; Kevin M Trulock; Divyang Patel; Saleem Toro; Laurie Ann Moennich; Niraj Varma; Mark J Niebauer; Eiran Z Gorodeski; Richard A Grimm; John Barnard; Anant Madabhushi; Mina K Chung
Journal:  Circ Arrhythm Electrophysiol       Date:  2020-06-14

Review 5.  Electrical management of heart failure: from pathophysiology to treatment.

Authors:  Frits W Prinzen; Angelo Auricchio; Wilfried Mullens; Cecilia Linde; Jose F Huizar
Journal:  Eur Heart J       Date:  2022-05-21       Impact factor: 35.855

6.  A single-centre prospective evaluation of left bundle branch area pacemaker implantation characteristics.

Authors:  L I B Heckman; J G L M Luermans; M Jastrzębski; B Weijs; A M W Van Stipdonk; S Westra; D den Uijl; D Linz; M Mafi-Rad; F W Prinzen; K Vernooy
Journal:  Neth Heart J       Date:  2022-04-05       Impact factor: 2.854

7.  Association between heart failure aetiology and magnitude of echocardiographic remodelling and outcome of cardiac resynchronization therapy.

Authors:  Mariëlle Kloosterman; Antonius M W van Stipdonk; Iris Ter Horst; Michiel Rienstra; Isabelle C Van Gelder; Marc A Vos; Frits W Prinzen; Matthias Meine; Kevin Vernooy; Alexander H Maass
Journal:  ESC Heart Fail       Date:  2020-01-28

Review 8.  Prevention of non-response to cardiac resynchronization therapy: points to remember.

Authors:  Huolan Zhu; Tong Zou; You Zhong; Chenguang Yang; Yirong Ren; Fang Wang
Journal:  Heart Fail Rev       Date:  2020-03       Impact factor: 4.214

9.  Sex differences in left ventricular electrical dyssynchrony and outcomes with cardiac resynchronization therapy.

Authors:  Daniel J Friedman; Kasper Emerek; Peter L Sørensen; Emily P Zeitler; Sarah A Goldstein; Sana M Al-Khatib; Peter Søgaard; Claus Graff; Brett D Atwater
Journal:  Heart Rhythm O2       Date:  2020-08-04

10.  Changes in QRS Area and QRS Duration After Cardiac Resynchronization Therapy Predict Cardiac Mortality, Heart Failure Hospitalizations, and Ventricular Arrhythmias.

Authors:  Osita Okafor; Abbasin Zegard; Peter van Dam; Berthold Stegemann; Tian Qiu; Howard Marshall; Francisco Leyva
Journal:  J Am Heart Assoc       Date:  2019-10-28       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.